<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4356">Deferoxamine</z:chebi> is a chelating agent used for the treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients requiring long-term blood transfusions </plain></SENT>
<SENT sid="1" pm="."><plain>Audiological testing of patients with B-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> and steroid-unresponsive Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> who were on long-term <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> treatment indicated a possible ototoxic side-effect </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study we have investigated this potential toxicity to the cochlea of experimental animals by monitoring electrophysiological responses to sound and also by histological evaluation of the cochlea </plain></SENT>
<SENT sid="3" pm="."><plain>In animals having <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> treatment, there were no significant changes in cochlear function or <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Data from acutely treated animals indicated an elevation of cochlear response thresholds together with morphological changes at the inner hair-cell level </plain></SENT>
<SENT sid="5" pm="."><plain>However, these changes were highly correlated with the respiratory <z:hpo ids='HP_0000716'>depression</z:hpo> caused by an <z:hpo ids='HP_0011009'>acute</z:hpo> general toxicity, rather than a direct ototoxic effect of <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> </plain></SENT>
</text></document>